In KANSHAS1 first-in-human study, 6-month outcome demonstrated: - Freedom from target limb amputation - 100%⁴
- Freedom from clinically driven target lesion revascularization(TLR) - 100%⁴
- Improvement in Rutherford classification – 93.3% of patients⁴
Please contact our sales representative for further information